Variables | n (%) | THR (95% CI) | TKR (95% CI) |
---|---|---|---|
Age, yrs | |||
< 55 | 6129 (62.8) | 1.05 (0.79–1.41) | 0.56 (0.37–0.83) |
55–69 | 2245 (23.0) | 5.17 (4.15–6.45) | 3.90 (3.03–5.02) |
≥ 70 | 1392 (14.3) | 6.91 (5.22–9.14) | 7.79 (5.98–10.15) |
Sex | |||
Female | 6061 (62.1) | 2.72 (2.25–3.27) | 2.56 (2.12–3.10) |
Male | 3705 (37.9) | 2.56 (2.00–3.29) | 1.39 (1.00–1.95) |
IMD | |||
1st quintile (least deprived) | 1535 (15.7) | 3.48 (2.50–4.85) | 2.48 (1.67–3.67) |
2nd quintile | 1137 (11.6) | 3.46 (2.34–5.12) | 2.33 (1.45–3.74) |
3rd quintile | 991 (10.2) | 3.53 (2.34–5.31) | 2.58 (1.61–4.16) |
4th quintile | 957 (9.8) | 2.05 (1.19–3.54) | 2.21 (1.31–3.73) |
5th quintile (most deprived) | 831 (8.5) | 1.39 (0.70–2.79) | 1.74 (0.94–3.24) |
Unknown | 4315 (44.2) | 2.36 (1.86–2.98) | 1.91 (1.47–2.48) |
Region | |||
North East | 129 (1.3) | 3.02 (0.98–9.38) | 1.98 (0.49–7.90) |
North West | 1818 (18.6) | 1.68 (1.09–2.61) | 1.93 (1.28–2.91) |
Yorkshire and Humber | 470 (4.8) | 2.57 (1.34–4.95) | 3.69 (2.14–6.35) |
East Midlands | 260 (2.7) | 0.62 (0.09–4.41) | 1.87 (0.60–5.81) |
West Midlands | 835 (8.6) | 2.18 (1.27–3.76) | 2.85 (1.77–4.59) |
East England | 647 (6.6) | 2.71 (1.50–4.89) | 1.47 (0.66–3.26) |
South West | 1105 (11.3) | 4.51 (3.16–6.46) | 2.54 (1.58–4.09) |
South Central | 843 (8.6) | 3.11 (1.93–4.99) | 1.45 (0.72–2.90) |
London | 634 (6.5) | 2.54 (1.37–4.73) | 1.78 (0.85–3.74) |
South East Coast | 855 (8.8) | 3.94 (2.57–6.05) | 2.81 (1.70–4.67) |
Northern Ireland | 647 (6.6) | 1.78 (0.89–3.56) | 2.00 (1.04–3.83) |
Scotland | 742 (7.6) | 2.75 (1.63–4.64) | 0.98 (0.41–2.34) |
Wales | 781 (8.0) | 2.59 (1.59–4.22) | 2.26 (1.34–3.82) |
NICE TA143* | |||
Pre- | 6601 (67.6) | 2.62 (2.23–3.09) | 2.11 (1.76–2.53) |
Post- | 3165 (32.4) | 2.82 (1.96–4.06) | 2.23 (1.48–3.36) |
↵* NICE TA143 refers to NICE guidance that first recommended the use of TNF-α inhibitors in ankylosing spondylitis in the UK (2008). IMD: indices of multiple deprivation; NICE: UK National Institute for Health and Care Excellence; TNF-α: tumor necrosis factor-α.